Search

Your search keyword '"Benson, Don M"' showing total 393 results
Start Over Author "Benson, Don M" Publication Type Academic Journals
393 results on '"Benson, Don M"'

1. Impact of chronic graft-versus-host disease on non-relapse mortality and survival.

Author

Jiang, Justin, Sigmund, Audrey M., Zhao, Qiuhong, Elder, Patrick, Vasu, Sumithira, Jaglowski, Samantha, Mims, Alice, Choe, Hannah, Larkin, Karilyn, Wall, Sarah, Grieselhuber, Nicole, William, Basem, Penza, Sam, Benson, Don M., Efebera, Yvonne A., and Sharma, Nidhi

Subjects
HEMATOPOIETIC stem cell transplantation, OLDER patients, STEM cell transplantation, GRAFT versus host disease, CHRONIC diseases
Abstract

Chronic graft-versus-host-disease (cGVHD) is one of the primary causes of morbidity and mortality for patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HCT). In recent years, advancements in allo-HCT have allowed a broader range of patients to receive transplant, particularly older patients. We sought to assess the impact of cGVHD on outcomes in patients undergoing allo-HCT, for older patients as compared to their counterparts. We performed a retrospective analysis of all patients who underwent allo-HCT 1999–2018. Our results showed that those patients who developed cGVHD by D + 180 had an increased risk and incidence of NRM as compared to those patients without cGVHD. There was no significant difference in outcomes for those patients with cGVHD by age (≥60 years old [yo] and <60 yo). These findings suggest the significant morbidity of cGVHD, regardless of age. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma

Author

Singer, Sara, Dean, Robert, Zhao, Qiuhong, Sharma, Nidhi, Abounader, Donna, Elder, Patrick, Hofmeister, Craig C., Benson, Don M., Rosko, Ashley, Penza, Sam, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, William, Basem M., Bolwell, Brian, Pohlman, Brad, Kalaycio, Matt, Jagadeesh, Deepa, Hill, Brian, Sobecks, Ronald, Devine, Steven M., Majhail, Navneet S., and Efebera, Yvonne A.

Published
2019
Full Text
View/download PDF

9. Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Author

Scoville, Steven D., Nalin, Ansel P., Chen, Luxi, Chen, Li, Zhang, Michael H., McConnell, Kathleen, Beceiro Casas, Susana, Ernst, Gabrielle, Traboulsi, Abd Al-Rahman, Hashi, Naima, Williams, Monica, Zhang, Xiaoli, Hughes, Tiffany, Mishra, Anjali, Benson, Don M., Saultz, Jennifer N., Yu, Jianhua, Freud, Aharon G., Caligiuri, Michael A., and Mundy-Bosse, Bethany L.

Published
2018
Full Text
View/download PDF

10. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas

Author

Singer, Sara, Sharma, Nidhi, Dean, Robert, Zhao, Qiuhong, Abounader, Donna, Elder, Patrick, Hofmeister, Craig C., Benson, Don M., Rosko, Ashley, Penza, Sam, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, William, Basem M., Bolwell, Brian, Pohlman, Brad, Kalaycio, Matt, Jagadeesh, Deepa, Hill, Brian, Sobecks, Ronald, Devine, Steven M., Majhail, Navneet S., and Efebera, Yvonne A.

Published
2019
Full Text
View/download PDF

15. Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease

Author

Vasu, Sumithira, Geyer, Susan, Bingman, Anissa, Auletta, Jeffery J., Jaglowski, Samantha, Elder, Pat, Donnell, Lynn O., Bradbury, Hillary, Kitzler, Rhonda, Andritsos, Leslie, Blum, William, Klisovic, Rebecca, Penza, Sam, Efebera, Yvonne, Hofmeister, Craig, Benson, Don M., Muthusamy, Natarajan, Lozanski, Gerard, and Devine, Steven M.

Published
2016
Full Text
View/download PDF

16. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Author

Harshman, Sean W., Canella, Alessandro, Ciarlariello, Paul D., Agarwal, Kitty, Branson, Owen E., Rocci, Alberto, Cordero, Hector, Phelps, Mitch A., Hade, Erinn M., Dubovsky, Jason A., Palumbo, Antonio, Rosko, Ashley, Byrd, John C., Hofmeister, Craig C., Benson, Don M., Jr., Paulaitis, Michael E., Freitas, Michael A., and Pichiorri, Flavia

Published
2016
Full Text
View/download PDF

17. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)

Author

Efebera, Yvonne A., Geyer, Susan, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, Bingman, Anissa, Blum, William, Klisovic, Rebecca, Hofmeister, Craig C., Benson, Don M., Penza, Sam, Elder, Patrick, Cortright, Katie, Kitzler, Rhonda, Coombes, Kevin, O'Donnell, Lynn, Daneault, Beth, Bradbury, Hillary, Zhang, Jianying, Chen, Xilin, Garman, Sabrina, Ranganathan, Parvathi, Yu, Xueyan, Hofstetter, Jessica, Yu, Jianhua, Garzon, Ramiro, Scrape, Scott R., Lozanski, Gerard, and Devine, Steven M.

Published
2016
Full Text
View/download PDF

19. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Author

Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Cho, Yoonjin, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., and Spurgeon, Stephen E.

Published
2014
Full Text
View/download PDF

21. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Author

Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., and Furman, Richard R.

Published
2014
Full Text
View/download PDF

24. Chunking, Rule Learning, and Multiple Item Memory in Rat Interleaved Serial Pattern Learning

Author

Fountain, Stephen B. and Benson, Don M.

Abstract

Nonhuman animals, like humans, appear sensitive to the structure of the elements of sequences, perhaps even when the structure relates nonadjacent elements. In the present study, we examined the contribution of chunking, rule learning, and item memory when rats learned serial patterns composed of two interleaved subpatterns. In one group, the first interleaved subpattern was a formally simple sequence, whereas in two other groups the first subpattern was formally more complex, containing 2 or 4 violation elements, respectively. In all groups, the second interleaved subpattern encountered was formally simple. Evidence from the study suggests that rats chunked their interleaved patterns into component subpatterns, that is, they cognitively sorted pattern elements to form chunks based on nonadjacent structural relationships that can be characterized as rules. They also learned interitem associations via traditional discrimination learning to use adjacent elements as compound or configural cues for later events in the sequence. Thus, the evidence suggests that rats used chunking, rule learning, and interitem association learning concurrently to master these complex patterns.

Published
2006
Full Text
View/download PDF

25. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma.

Author

Sharma, Nidhi, Benson, Evan, Zhao, Qiuhong, Nunnelee, Jordan, Cottini, Francesca, Elder, Patrick, Rosko, Ashley, Bumma, Naresh, Khan, Abdullah, Umyarova, Elvira, Devarakonda, Srinivas, Efebera, Yvonne A., and Benson, Don M.

Subjects
STEM cell transplantation, MULTIPLE myeloma, SURVIVAL rate, MELPHALAN, PROGRESSION-free survival
Abstract

The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple myeloma (MM) is 200 mg/m2 of intravenous melphalan; however, a dose of 140 mg/m2 is often used when concerns exist related to patient age, performance status, organ function, and other factors. It is unclear whether a lower dose of melphalan impacts post-transplant survival outcomes. We performed a retrospective review of 930 patients with MM who underwent ASCT with 200 mg/m2 versus 140 mg/m2 melphalan. On univariable analysis, no difference in progression-free survival (PFS) was observed, however, an overall survival (OS) benefit was observed in patients receiving 200 mg/m2 melphalan (p = 0.04). Multivariable analyses showed patients receiving 140 mg/m2 faired no worse than those receiving 200 mg/m2. While a subset of younger patients with normal renal function may achieve superior OS with a standard dose of 200 mg/m2 melphalan, these findings suggest an opportunity to individualize the ASCT preparative regimen to optimize outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Author

Benson, Don M., Jr, Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., and Caligiuri, Michael A.

Published
2010
Full Text
View/download PDF

29. Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Author

Romagné, Francois, André, Pascale, Spee, Pieter, Zahn, Stefan, Anfossi, Nicolas, Gauthier, Laurent, Capanni, Marusca, Ruggeri, Loredana, Benson, Don M., Jr, Blaser, Bradley W., Della Chiesa, Mariella, Moretta, Alessandro, Vivier, Eric, Caligiuri, Michael A., Velardi, Andrea, and Wagtmann, Nicolai

Published
2009
Full Text
View/download PDF

30. 466 - Impact of Opioid Use after Blood and Marrow Transplantation (BMT): A Single-Center Analysis

Author

Soror, Noha, Keiter, Ashleigh, Zhao, Qiuhong, Elder, Patrick, Puto, Marcin, Penza, Sam, Brammer, Jonathan E., Efebera, Yvonne A., Benson, Don M, Vasu, Sumithira, Mims, Alice, Blaser, Bradley, Choe, Hannah, Larkin, Karilyn, Grieselhuber, Nicole, Wall, Sarah A., Rosko, Ashley, Chaudhry, Maria, Bumma, Naresh, Khan, Abdullah, Devarakonda, Srinivas, Saad, Ayman, Jaglowski, Samantha, and William, Basem M.

Published
2021
Full Text
View/download PDF

33. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

Author

Christian, Beth A., Poi, Ming, Jones, Jeffrey A., Porcu, Pierluigi, Maddocks, Kami, Flynn, Joseph M., Benson, Don M., Jr, Phelps, Mitch A., Wei, Lai, Byrd, John C., Wegener, William A., Goldenberg, David M., Baiocchi, Robert A., and Blum, Kristie A.

Published
2015
Full Text
View/download PDF

36. Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies

Author

Hamadani, Mehdi, Blum, William, Phillips, Gary, Elder, Patrick, Andritsos, Leslie, Hofmeister, Craig, O'Donnell, Lynn, Klisovic, Rebecca, Penza, Sam, Garzon, Ramiro, Krugh, David, Lin, Thomas, Bechtel, Thomas, Benson, Don M., Byrd, John C., Marcucci, Guido, and Devine, Steven M.

Published
2009
Full Text
View/download PDF

38. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

Author

Kolitz, Jonathan E., George, Stephen L., Benson, Don M., Jr, Maharry, Kati, Marcucci, Guido, Vij, Ravi, Powell, Bayard L., Allen, Steven L., DeAngelo, Daniel J., Shea, Thomas C., Stock, Wendy, Bakan, Courtney E., Hars, Vera, Hoke, Eva, Bloomfield, Clara D., Caligiuri, Michael A., and Larson, Richard A.

Published
2014
Full Text
View/download PDF

39. Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.

Author

Jiang, Justin, Sigmund, Audrey M., Zhao, Qiuhong, Elder, Patrick, Benson, Don M., Vasu, Sumithira, Jaglowski, Samantha, Mims, Alice, Choe, Hannah, Larkin, Karilyn, Brammer, Jonathan E., Wall, Sarah, Grieselhuber, Nicole, Saad, Ayman, Penza, Sam, Efebera, Yvonne A., and Sharma, Nidhi

Subjects
BLOOD disease treatment, GRAFT versus host disease, TREATMENT effectiveness, BLOOD diseases, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, LONGITUDINAL method
Abstract

Simple Summary: Stem cell transplantation from a donor can be a potential cure for several blood cancers. We have maintained the characteristics and outcomes of patients receiving these transplants at our institution, the Ohio State University, since 1984. In this study, we looked at these outcomes, including how long patients lived after transplant, how long before their cancer came back, and if they developed other complications related to receiving a transplant, and evaluated how they changed over the years. We conclude that patients are now living longer with a lower chance of their cancer returning or of developing other complications, likely as a result of improvements in supportive care for transplant patients. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for many hematological disorders, but is often complicated by relapse of the underlying disease, graft-versus-host disease (GVHD), and infectious complications. We conducted a retrospective analysis on patients undergoing allo-SCT from 1984 to 2018 to better understand how survival has changed longitudinally with therapeutic advancements made to mitigate these complications. Method: We analyzed data from 1943 consecutive patients who received allo-SCT. Patients were divided into groups (gps) based on the year (yr) of transplant. Primary endpoints were overall survival (OS), progression free survival (PFS), and GVHD-free relapse-free survival (GRFS). Secondary endpoints were the cumulative incidences of grade II–IV and grade III–IV acute GVHD (aGVHD), chronic GVHD (cGVHD), and non-relapse mortality (NRM). Results: Our study found statistically significant improvements in OS, PFS, and GRFS. Five-year PFS among the groups increased from 24% to 48% over the years. Five-year OS increased from 25% to 53%. Five-year GRFS significantly increased from 6% to 14%, but remained relatively unchanged from 2004 to 2018. Cumulative incidences of grade II–IV aGVHD increased since 2009 (p < 0.001). However, cumulative incidence of NRM decreased since 2004 (p < 0.001). Conclusions: Our data show improved OS, PFS, and GRFS post allo-SCT over decades. This may be attributed to advances in supportive care and treatments focused on mitigation of GVHD and relapse. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma.

Author

Nunnelee, Jordan, Cottini, Francesca, Zhao, Qiuhong, Faisal, Muhammad Salman, Elder, Patrick, Rosko, Ashley, Bumma, Naresh, Khan, Abdullah, Umyarova, Elvira, Devarakonda, Srinivas, Benson, Don M., Efebera, Yvonne A., and Sharma, Nidhi

Subjects
MULTIPLE myeloma, STEM cell transplantation, PATIENT preferences, SURVIVAL rate, PLASMACYTOMA
Abstract

Maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM) is the standard treatment and recommended to be continued until disease progression. However, in the real world, patients discontinue treatment due to various reasons. We sought to determine the effect of early versus late discontinuation on survival outcomes in MM patients who underwent ASCT at The Ohio State University. We retrospectively reviewed 340 patients who underwent ASCT from 2005 to 2016 and received maintenance therapy for at least six months without progression. We compared the outcomes of patients who received maintenance for three years or less (early group) to the patients who continued maintenance beyond three years (late group). Lenalidomide (89%) and bortezomib (10%) were the most common agents used for maintenance chemotherapy. In Kaplan–Meier analysis, patients in the late group had prolonged progression-free (PFS) (p < 0.001) and overall survival (OS) (p < 0.001). The 5-year estimated OS in late group was 96% vs. 79% in the early group and 5-year PFS was 80% in late group vs. 50% in the early group. The most common reasons for discontinuation of maintenance in early group were adverse events (55.9%) and patient preference (22.5%). For the late group, it was disease progression (23.9%) and adverse events (14.3%). Fifty-five percent of patients in the late group were still on maintenance treatment at the last follow-up. Continuation of maintenance therapy was thus associated with improved outcomes, while adverse events prevented most patients from continuing treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience.

Author

Nunnelee, Jordan, Cottini, Francesca, Zhao, Qiuhong, Faisal, Muhammad Salman, Elder, Patrick, Rosko, Ashley, Bumma, Naresh, Khan, Abdullah, Devarakonda, Srinivas, Benson, Don M., Efebera, Yvonne, and Sharma, Nidhi

Subjects
MULTIPLE myeloma treatment, RETROSPECTIVE studies, ACQUISITION of data, AUTOGRAFTS, TREATMENT effectiveness, CANCER patients, MEDICAL records, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, MULTIPLE myeloma, HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, EVALUATION
Abstract

Simple Summary: The outcomes of patients with multiple myeloma have significantly improved over the years, following autologous stem cell transplant and the introduction of novel agents. In this study, we performed a retrospective survival analysis on newly diagnosed MM patients receiving ASCT from 1992–2016 at the Ohio State University. We observed that newly diagnosed MM patients' survival and responses to standard of care treatment have improved dramatically since 1992, primarily due to the inclusion of novel and maintenance therapies. There was an improvement in patient remission status, PFS, and OS, suggesting that evolving standards of therapy for MM are enhancing patient outcomes. These findings highlight the importance for newer interventions to build on prior successes. Multiple myeloma (MM) represents 1.8% of all new cancer cases in the U.S. While not curable, advances in treatment, including autologous stem cell transplant (ASCT) and maintenance therapy, have dramatically improved progression-free survival (PFS) and overall survival (OS). We performed a retrospective survival analysis on newly diagnosed MM (NDMM) patients receiving ASCT from 1992–2016 at the Ohio State University. A total of 1001 consecutive NDMM patients were eligible. Patients were split into five groups based on historic changes in novel agents for the treatment of MM. Across the years (1992–2016), there was a statistically significant improvement in both PFS (p < 0.01) and OS (p < 0.01). Significant improvements in both PFS and OS were seen in patients ≤65 years (p < 0.001 and p = 0.002) and >65 years old (p < 0.001 and p = 0.001), respectively. Improved PFS and OS were seen in both standard-risk (p < 0.001 and p < 0.001) and high-risk patients (p < 0.001 and p = 0.019). The post-transplant response showed statistically significant improvement across the years (p < 0.01). Survival rates for NDMM patients have significantly improved primarily due to the inclusion of novel therapies and post-ASCT maintenance. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results